These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

542 related items for PubMed ID: 10953027

  • 1. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
    Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK.
    J Clin Invest; 2000 Aug; 106(4):523-31. PubMed ID: 10953027
    [Abstract] [Full Text] [Related]

  • 2. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
    Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE.
    Arterioscler Thromb Vasc Biol; 2001 Mar; 21(3):365-71. PubMed ID: 11231915
    [Abstract] [Full Text] [Related]

  • 3. Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages.
    Iwashima Y, Eto M, Hata A, Kaku K, Horiuchi S, Ushikubi F, Sano H.
    Biochem Biophys Res Commun; 2000 Oct 22; 277(2):368-80. PubMed ID: 11032732
    [Abstract] [Full Text] [Related]

  • 4. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism.
    Kumar AP, Piedrafita FJ, Reynolds WF.
    J Biol Chem; 2004 Feb 27; 279(9):8300-15. PubMed ID: 14668325
    [Abstract] [Full Text] [Related]

  • 5. Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor 4alpha.
    Malerød L, Sporstøl M, Juvet LK, Mousavi A, Gjøen T, Berg T.
    Biochem Biophys Res Commun; 2003 Jun 06; 305(3):557-65. PubMed ID: 12763030
    [Abstract] [Full Text] [Related]

  • 6. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
    Wang M, Tafuri S.
    J Cell Biochem; 2003 May 01; 89(1):38-47. PubMed ID: 12682906
    [Abstract] [Full Text] [Related]

  • 7. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.
    Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM.
    Cell; 1998 Apr 17; 93(2):241-52. PubMed ID: 9568716
    [Abstract] [Full Text] [Related]

  • 8. CD36 in atherosclerosis. The role of a class B macrophage scavenger receptor.
    Nicholson AC, Febbraio M, Han J, Silverstein RL, Hajjar DP.
    Ann N Y Acad Sci; 2000 May 17; 902():128-31; discussion 131-3. PubMed ID: 10865832
    [Abstract] [Full Text] [Related]

  • 9. PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells.
    Chiba Y, Ogita T, Ando K, Fujita T.
    Biochem Biophys Res Commun; 2001 Aug 24; 286(3):541-6. PubMed ID: 11511093
    [Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.
    Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller DE, Wright SD, Thieringer R.
    J Biol Chem; 2001 Apr 20; 276(16):12629-35. PubMed ID: 11278270
    [Abstract] [Full Text] [Related]

  • 11. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells.
    Covey SD, Krieger M, Wang W, Penman M, Trigatti BL.
    Arterioscler Thromb Vasc Biol; 2003 Sep 01; 23(9):1589-94. PubMed ID: 12829524
    [Abstract] [Full Text] [Related]

  • 12. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.
    Chen Z, Ishibashi S, Perrey S, Osuga Ji, Gotoda T, Kitamine T, Tamura Y, Okazaki H, Yahagi N, Iizuka Y, Shionoiri F, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N.
    Arterioscler Thromb Vasc Biol; 2001 Mar 01; 21(3):372-7. PubMed ID: 11231916
    [Abstract] [Full Text] [Related]

  • 13. Lysophosphatidic acid induces neointima formation through PPARgamma activation.
    Zhang C, Baker DL, Yasuda S, Makarova N, Balazs L, Johnson LR, Marathe GK, McIntyre TM, Xu Y, Prestwich GD, Byun HS, Bittman R, Tigyi G.
    J Exp Med; 2004 Mar 15; 199(6):763-74. PubMed ID: 15007093
    [Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator-activated receptor gamma-mediated NF-kappa B activation and apoptosis in pre-B cells.
    Schlezinger JJ, Jensen BA, Mann KK, Ryu HY, Sherr DH.
    J Immunol; 2002 Dec 15; 169(12):6831-41. PubMed ID: 12471115
    [Abstract] [Full Text] [Related]

  • 15. Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal.
    Ishii T, Itoh K, Ruiz E, Leake DS, Unoki H, Yamamoto M, Mann GE.
    Circ Res; 2004 Mar 19; 94(5):609-16. PubMed ID: 14752028
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension.
    Sakamoto H, Aikawa M, Hill CC, Weiss D, Taylor WR, Libby P, Lee RT.
    Circulation; 2001 Jul 03; 104(1):109-14. PubMed ID: 11435347
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
    Agostini M, Gurnell M, Savage DB, Wood EM, Smith AG, Rajanayagam O, Garnes KT, Levinson SH, Xu HE, Schwabe JW, Willson TM, O'Rahilly S, Chatterjee VK.
    Endocrinology; 2004 Apr 03; 145(4):1527-38. PubMed ID: 14657011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.